Efficacy of zenocutuzumab in NRG1 fusion-positive cancer
A basket study evaluated the efficacy of zenocutuzumab, a bispecific antibody against HER2 and HER3, in patients with solid tumors harboring NRG1 fusions. Among 158 patients, 30% had a response (including 42% with pancreatic cancer).
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
February 5, 2025
|
| In: |
The New England journal of medicine
Year: 2025, Jahrgang: 392, Heft: 6, Pages: 566-576 |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMoa2405008 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1056/NEJMoa2405008 Verlag, lizenzpflichtig, Volltext: https://www.nejm.org/doi/full/10.1056/NEJMoa2405008 |
| Verfasserangaben: | Alison M. Schram, Koichi Goto, Dong-Wan Kim, Teresa Macarulla, Antoine Hollebecque, Eileen M. O’Reilly, Sai-Hong Ignatius Ou, Jordi Rodon, Sun Young Rha, Kazumi Nishino, Michaël Duruisseaux, Joon Oh Park, Cindy Neuzillet, Stephen V. Liu, Benjamin A. Weinberg, James M. Cleary, Emiliano Calvo, Kumiko Umemoto, Misako Nagasaka, Christoph Springfeld, Tanios Bekaii-Saab, Grainne M. O’Kane, Frans Opdam, Kim A. Reiss, Andrew K. Joe, Ernesto Wasserman, Viktoriya Stalbovskaya, Jim Ford, Shola Adeyemi, Lokesh Jain, Shekeab Jauhari, and Alexander Drilon, for the eNRGy Investigators |
| Zusammenfassung: | A basket study evaluated the efficacy of zenocutuzumab, a bispecific antibody against HER2 and HER3, in patients with solid tumors harboring NRG1 fusions. Among 158 patients, 30% had a response (including 42% with pancreatic cancer). |
|---|---|
| Beschreibung: | Gesehen am 09.12.2025 |
| Beschreibung: | Online Resource |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMoa2405008 |